Geron (GERN) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Geron (GERN) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -6.81% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 92.37% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.21% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -84.64% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -2.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.19% |
| Mar 31, 2026 | 81.94% |
| Dec 31, 2025 | -22.02% |
| Sep 30, 2025 | 30.76% |
| Jun 30, 2025 | 75.77% |
| Mar 31, 2025 | 64.30% |
| Dec 31, 2024 | 54.63% |
| Sep 30, 2024 | 40.99% |
| Jun 30, 2024 | -36.78% |
| Mar 31, 2024 | -44.99% |
| Dec 31, 2023 | -21.75% |
| Sep 30, 2023 | -9.29% |
| Jun 30, 2023 | -68.39% |
| Mar 31, 2023 | -24.33% |
| Dec 31, 2022 | -33.46% |
| Sep 30, 2022 | -53.69% |
| Jun 30, 2022 | 1.12% |
| Mar 31, 2022 | -5.75% |
| Dec 31, 2021 | -34.82% |
| Sep 30, 2021 | -35.13% |